Recent Winners


+180%
PLX
Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
+157%
OREX
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+58%
XGTI
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
+36%
CYNO
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+27%
ICHR
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+20%
SN
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
+16%
CX
Alert Price: $7.97
High Price: $9.30
Results: 16% in 10 Days
+16%
ACAD
Alert Price: $32.03
High Price: $37.09
Results: 16% in 26 Days
+15%
PVG
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
+12%
OCLR
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
+12%
ACET
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
+12%
COW
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
+10%
HWKN
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
+9%
LLY
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

Top Catalysts For The Week Ending February 17 2017


LightPath Technologies = Beats on earnings and revenue

Editas Medicine = Patent Office Decision Favorable to Broad Institute in CRISPR

Agilent Technologies = Beats on Earnings and Revenue

IPG Photonics = Beats on earnings and revenue

Sonus Networks = Rising Money Flow On Institutional Buying

KapStone Paper = Confirms Raising Containerboard Prices

Popeyes Louisiana Kitchen = Hearing Takeover Rumors Circulating

XPO Logistics = Rising Revenue and Money Flow

Trading Lessons

Mainstream Financial News

Archives

Medtronic Gets Japanese Approval for Micra Transcatheter Pacing System

February 17, 2017: Medtronic announced Japan regulatory approval for the world’s smallest pacemaker, the Micra(TM) Transcatheter Pacing System (TPS). Japan’s Pharmaceuticals and Medical Device Agency (PMDA) granted approval for Micra based on positive data from the Medtronic Micra TPS Global Clinical Trial, which enrolled 744 patients and evaluated the safety and efficacy of the device (Read More….)

Ocular Therapeutix Rising Money Flow After Resubmits NDA for Dextenza

February 12, 2017: Biotechnology firm Ocular Therapeutix’s stock is surging higher on rising money flow after the company announced on January 23, 2017, that it had resubmitted an NDA for Dextenza. Ocular Therapeutix announced on January 23, 2017, that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) (Read More….)

Sell ACADIA Pharmaceuticals for a 15.8% Win

February 11, 2017: Selling ACADIA Pharmaceuticals Monday for about a 15.8% win. Congratulations if you were able to make money on the trade.

February 5, 2017: ACADIA Pharmaceuticals Inc reportedly receives takeover approach from AstraZeneca according to an article on StreetInsider. Source: http://www.streetinsider.com/Hot+M+and+A/ACADIA+%28ACAD%29+Said+to+Receive+Takeover+Offer+from+AstraZeneca+%28AZN%29+-+Source/12496195.html

Pfizer may also have interest in acquiring lead drug candidate Nuplazid but (Read More….)

Zimmer Biomet Announces International Release of the Innovative Subchondroplasty Procedure

February 07, 2017: Zimmer Biomet announced today the international release of the Subchondroplasty (SCP) Procedure. The Company received CE Mark approval for the commercialization of its SCP Procedure to facilitate distribution in the European Union (EU) and other countries that recognize the CE Mark. Zimmer Biomet also received approval for distribution in Canada, Singapore, Malaysia (Read More….)

Cellectis Gets Investigational New Drug Approval From FDA For Phase 1 Trials With UCART123

February 6, 2017: Cellectis announced that it has received an Investigational New Drug approval from the FDA to conduct Phase 1 clinical trials with UCART123, the Company’s most advanced, wholly owned TALEN gene-edited product candidate, in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks the first allogeneic, “off-the-shelf” (Read More….)

Lannett Beats On Earnings and Revenue

February 01, 2017: Lannett Company reports Q2 EPS of $0.92 versus the $0.83 estimate. Revenue also beat coming in at $170.9 million versus the $169 million estimate.

The CEO said, “Higher sales across a number of products and the addition of KU’s operations were key drivers to the 35% increase in our fiscal 2017 (Read More….)

Regeneron Pharmaceuticals Gets Approval of Kevzara With Sanofi For Rheumatoid Arthritis

February 1, 2017: Regeneron Pharmaceuticals, Inc. and Sanofi today announced that Health Canada approved Kevzara™ (sarilumab), an interleukin-6 (IL-6) receptor antibody, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

Kevzara (Read More….)

Ironwood Pharmaceuticals Reports Positive Top-Line Results from Phase III Linaclotide Trial

January 29, 2017: Astellas Pharma and Ironwood Pharmaceuticals announced today top-line results indicating that the Phase III clinical trial of linaclotide conducted in Japan in adults with chronic constipation (CC) met its primary endpoint.

Linaclotide is approved in Japan as the first prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C). Linaclotide is (Read More….)

Top Performing Stocks On GuerillaStockTrading For Week Ending January 27 2017

OREX continues to be our dominant stock pick up a whopping +80% since profiled on GuerillaStockTrading.com

The biggest new gainer this last week was PLX which rocketed higher after it received FDA Orphan Drug Designation for CTP-656 for the treatment of Cystic Fibrosis.

Another big climber was CGIX after it launched its entry into comprehensive (Read More….)

Aratana Therapeutics Transiting From R&D To Revenue Producing Company

January 27, 2017: Aratana Therapeutics hot stock tip sent in through GuerillaStockTrading website. The catalyst is that with four FDA approvals for dogs, the company is transitioning from an R&D company to a revenue producing company this year. Thank you for sending in this hot stock tip with the catalyst.

January 24, 2017: Elanco Animal (Read More….)

Jefferies Reiterates TherapeuticsMD As Top Small-cap Pick For 2017

January 25, 2017: Jefferies reiterates TherapeuticsMD with a Buy rating and a price target of $18. Jefferies says that the investor tour of local compounding pharmacy provided unique insights into ‘001 market opportunity and reinforced our view that the bioidentical E+P VMS market is at a minimum 5.1M scrips or $714-$893M in sales (assumes 100% (Read More….)

Jazz Pharmaceuticals Leerink Reiterates Outperform Rating, Price Target $182

January 18, 2017: Leerink reiterates their Outperform rating on Jazz Pharmaceuticals and sets a price target of $182 after yesterday evenings FDA updates regarding a generic Xyrem (naracolepsy) application appear to be a net-positive for JAZZ as the FDA concurrently ruled (in a citizens petition [CP]) that it won’t allow generic substitutes to carve-out safety/dosing (Read More….)

Horizon Pharma Guides On Track To Deliver $2 Billion In Sales by 2020

January 10, 2017: In a JPM slide presentation, Horizon Pharma says it’s on track to deliver $2 billion in total net sales by 2020.

December 22, 2016: Horizon Pharma announces that it has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 13/610,580, entitled “Methods of (Read More….)

Novo Nordisk Marketing Authorization Granted by European Commission For Fiasp

January 10, 2017: Novo Nordisk A/S B announces marketing authorization granted by European Commission for Fiasp for treatment of diabetes in adults. Novo Nordisk expects to launch Fiasp in the first European countries in the first half of 2017. The authorisation covers all 28 European Union member states.

Fiasp is the brand name for fast-acting (Read More….)

PTC Therapeutics Breaks Above 200 MA On Positive CHMP Opinion

January 9, 2017: Biotechnology firm PTC Therapeutics’ stock broke above the 200 day MA today as it received notification from the European Commission (EC) of its adoption of a positive decision granting annual renewal of the conditional marketing authorization for Translarna (ataluren). The positive decision is based on the recent renewal recommendation by the Committee (Read More….)

Bottom Feeding In DexCom After Cowen Reiterates Outperform Rating

January 8, 2017: Traders are bottom feeding in DexCom stock after Cowen says DexCom should be close to a bottom. Cowen reiterates an Outperform rating on DexCom, and sets a price target of $90. Cowen thinks DexCom should be close to a bottom and sees little risk to their 2017 30% Y/Y growth forecast (regardless (Read More….)

CTI BioPharma FDA Hold Removed and Positive PERSIST-2 Phase 3 Data

January 7, 2017: Biotechnology firm CTI BioPharma announced on January 4, 2017 that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) on all clinical trials conducted under the Investigational New Drug (IND) application for pacritinib has now been removed. The Company’s complete response submission included, among other items, (Read More….)

Ionis Pharmaceuticals Enters Into Strategic Collaboration With Novartis

January 6, 2016: Ionis Pharmaceuticals and Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., announced an exclusive, worldwide option and collaboration agreement with Novartis to develop and commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx. Ionis and Akcea are eligible to receive $225 million in near-term payments, including an immediate $75 million upfront option payment and a $100 (Read More….)

Analyst Actions and Breaking News

Overnight Analyst Actions:

Raised: None

Initiates:

MBLY Buy Monness Crespi

Cuts: None

Overnight Headlines By Ticker:

ITEK Inotek Pharmaceuticals Corporation

1/3 07:34 Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma fails to meet primary endpoint. GuerillaStockTrading coverage of this company dropped.

(Read More….)

Teligent Gets FDA Approval For Three ANDAs

January 03, 2017: Biotechnology firm Teligent announced it has received approval of three of the Company’s abbreviated new drug applications (ANDAs) from the U.S. Food and Drug Administration (FDA) of Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram and 1 mg/gram, Clindamycin Phosphate Topical Solution USP, 1% and Flurandrenolide Ointment USP, 0.05%. These approvals were (Read More….)

Novartis Alcon Receives FDA Approval For AcrySof

February 28, 2016: Novartis announced that the FDA has approved Afinitor for the treatment of some tumors. The FDA has approved everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. The approval was based on demonstration of improvement in progression-free survival (PFS) in a multicenter, randomized (2:1), placebo-controlled trial of everolimus 10 mg orally once daily plus best supportive care (BSC) to placebo plus BSC. (Read More….)

Opko Health Huge Gap Down On Phase 3 Trial Problems

December 30, 2016: Opko Health stock did a huge gap down today after a trading halt was put on the stock. Here’s what happened. Opko Health Phase 3 clinical study of hGH-CTP in growth hormone deficient adults showed there was no statistical difference between hGH-CTP and the placebo. However, after unblinding the study, OPKO identified (Read More….)

Eli Lilly Sell For 8.8% Win In 12 Days

December 29, 2016: Sell Eli Lilly for an 8.8% gain in 12 trading days. Congratulations if you were able to make money on the trade.

December 16, 2016: Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro in people with Type 1 diabetes. This is a successful completion of an (Read More….)